Panelists discuss how subcutaneous immune checkpoint inhibitors offer comparable efficacy and safety to intravenous formulations while reducing treatment time, improving patient quality of life through shorter clinic visits and eliminating venous access challenges, and creating operational efficiencies in oncology practices through streamlined workflows and reduced infusion chair demands.
Panelists discuss how multidisciplinary care, biomarker testing, personalized therapy selection, adverse event management, patient education, and long-term follow-up can be optimized to improve outcomes and quality of life for patients with ALK-positive non-small cell lung cancer.
Virginia Kaklamani, MD, DSc; and Megan Kruse, MD, discuss how advances in hormone receptor-positive metastatic breast cancer treatment, including ESR1 mutation testing and elacestrant therapy, help physicians optimize patient care and improve outcomes through personalized treatment selection.
Javier Pinilla, MD, PhD, and Lauren Verity Moore, DNP, MSN, AGACNP-BC, discuss how the evolving landscape of chronic myeloid leukemia (CML) treatment has improved patient outcomes through new drug formulations such as nilotinib without fasting requirements, emphasizing the critical roles of medication adherence, comprehensive adverse effect management, multidisciplinary care teams, and shared decision-making to ensure both effective disease control and optimal quality of life for patients living with this now-manageable chronic condition.
Panelists discuss how a patient-centered approach, shared decision-making, and clear communication between physicians, patients, and caregivers are essential in improving care, treatment adherence, and long-term management for individuals with paroxysmal nocturnal hemoglobinuria (PNH).
This program was made possible with support from Novartis Pharmaceuticals.
Experts explore chronic graft-versus-host disease (cGVHD), discussing its symptoms, patient impact, treatment approaches including emerging therapies like axatilimab, and strategies for symptom management and patient education, while emphasizing the importance of multidisciplinary care and looking towards future advancements in GVHD management.
A panel of experts on chronic myeloid leukemia have a comprehensive discussion on patient-centered care and the important role of shared decision-making in the optimal treatment of patients with CML.
This program was made possible with support from Novartis Pharmaceuticals.
Christine Cooper, RN, BSN, and Aaron Gerds, MD, MS, discuss optimizing outcomes and quality-of-life in patients with myelofibrosis, the current treatment options and promising advances, and side-effect management.
